In patients with type 2 diabetes, both supervised exercise and treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) liraglutide may improve cardiac function. We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin. Early diastolic myocardial tissue velocity was improved by exercise in the placebo group (mean AE standard deviation [s.d.] −7.1 AE 1.6 to −7.7 AE 1.8 cm/s, P = .01), but not in the liraglutide group (−7.1 AE 1.4 to −7.0 AE 1.4 cm/s, P = .60; between groups, P = .02). Similarly, the mean AE s.d. ratio of early and atrial mitral annular tissue velocities improved in the placebo group (1.0 AE 0.4 to 1.2 AE 0.4, P = .003), but not in the liraglutide group (1.0 AE 0.3 to 1.0 AE 0.3, P = .87; between groups, P = .03). We found no significant differences in heart rate, left ventricular (LV) structure or function within or between the groups.
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In conclusion, the addition of liraglutide to exercise in sedentary patients with dysregulated type 2 diabetes may blunt the suggested beneficial effect of exercise on LV diastolic function.
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| INTRODUCTION
In patients with type 2 diabetes, studies examining the effect of exercise on cardiac function have had conflicting results, and the effect of exercise intervention seems to be related to the type, duration and intensity of the exercise. Accordingly, in a study in 223 patients undergoing a 12-month exercise intervention, myocardial function was only improved in response to moderate and vigorous exercise. Heart rate was measured at baseline and after the intervention. Within-group changes were examined with paired t tests, and between-groups changes with analysis of covariance.
| RESULTS
One participant was excluded from the analyses before the unblinding because of a protocol violation (echocardiography performed without adequate time for rest after exercise). The results are shown in Table 1 . While there was a significant improvement in diastolic function assessed as early diastolic mitral annular tissue velocity in the placebo group of 0.6 cm/s, it was insignificantly decreased in the liraglutide group by 0.1 cm/s (difference between the 2 groups, P = .02 [ Figure 1] ). The same pattern was found regarding the ratio of early and atrial mitral annular myocardial tissue velocities, which estimate the relative contribution of the passive LV filling to the active contribution (atrial contraction [ Figure 1 ]). We found no changes in heart rate in any of the groups (placebo: 70 AE 12 to 69 AE 13 bpm, P = .50; liraglutide: 70 AE 9 to 71 AE 9 bpm, P = .82;
between groups, P = .32) and no significant differences in LV structure, including wall diameters, internal dimension and mass within or between the placebo and the liraglutide groups were observed. LV systolic function, ejection fraction and global longitudinal strain, were also similar within and between the 2 groups.
| DISCUSSION
The primary finding of the present study was that the anticipated, individual contribution of exercise and liraglutide to improvement of LV diastolic function was lacking when the 2 were combined in sedentary patients with type 2 diabetes inadequately controlled on diet and/or metformin treatment.
LV diastolic function is impaired in patients with type 2 diabetes 6 and overt diastolic dysfunction is associated with increased risk of heart failure and mortality. 7 Results from previous studies in patients with type 2 diabetes have been conflicting with regard to the effect of exercise on cardiac function (perhaps reflecting the heterogeneity of the study populations and type of exercise intervention), but seems to be related to type, duration and intensity of the training. In the light of the previously reported beneficial effect of liraglutide on cardiac function, 2 our results are surprising because the hypothesized additive effect of exercise and liraglutide on cardiac function did not occur in the present study. A possible explanation may be an increase in heart rate, which has been observed with treatment with liraglutide 13 and has been found to be associated with worsening of measures of diastolic function 14 ; however, we did not find significant differences in heart rates between the placebo and the liraglutide groups, although heart rate decreased in the placebo group in response to exercise and increased in the liraglutide group.
This lack of increase in heart rate associated with liraglutide could be attributed to the exercise intervention or it could be a question of lack of power in the present study to detect small changes in heart rate. Taken together, these observations underline the complex and poorly described interaction between the cardiovascular system, exercise and liraglutide that may have caused the changes observed in this study.
The lack of effect on LV diastolic function in the liraglutide plus exercise group should arguably raise some concern; however, liraglutide was shown to reduce cardiovascular disease in the Liraglutide
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome
Results (LEADER) trial 13 and, in a recent retrospective study, incretinbased therapy was associated with an overall benefit on risk of developing heart failure. 15 Yet, recently, liraglutide was tested in patients with chronic heart failure with and without type 2 diabetes in a randomized, double-blind, placebo-controlled setting and showed no effect on cardiac function and remodelling. In fact, in that study, treatment with liraglutide was associated with a significantly higher incidence of serious cardiac events, despite a decrease in ratio of peak early mitral inflow velocity and peak early diastolic myocardial velocity. 16 Hence, to address the potential detrimental effect of liraglutide on cardiac function caused by increased heart rate or other unidentified mechanisms, large, randomized clinical trials with long follow-up time are warranted. Bold text indicates P < .05.
Abbreviations: A, peak atrial mitral inflow velocity; a 0 , peak atrial diastolic myocardial velocity; CI, confidence interval; E, peak early mitral inflow velocity; e 0 , peak early diastolic myocardial velocity; s 0 , peak systolic myocardial velocity.
The results of the present study should be interpreted with caution because not all markers of diastolic function were affected by supervised exercise and liraglutide; most notably, the ratio of peak early mitral inflow velocity and peak early diastolic myocardial velocity, that in a previous study was found to be a strong predictor of heart failure and mortality in patients with type 2 diabetes, 7 actually decreased in the liraglutide group. As this was a sub-study not designed to detect changes in myocardial function, the absence of significant effects on heart rate, systolic and certain diastolic measurements could be attributable to lack of power. Also, more than 
